Document is current
Any future updates will be listed below
-
Authors
van der Ende, Nadinda A. M. https://orcid.org/0000-0003-4681-8388
Roozenbeek, Bob
Smagge, Lucas E. M.
Luijten, Sven P. R.
Aerden, Leo A. M.
Kraayeveld, Petra
van den Wijngaard, Ido R.
Lycklama à Nijeholt, Geert J.
den Hertog, Heleen M.
Flach, H. Zwenneke
Wallace, Alexis C.
Gurewich, Victor
del Zoppo, Gregory J.
Meurer, William J.
Lingsma, Hester F.
van der Lugt, Aad
Dippel, Diederik W. J.
,
Dippel, Diederik
van der Lugt, Aad
van der Ende, Nadinda
Roozenbeek, Bob
de Maat, Moniek
Aerden, Leo
van den Wijngaard, Ido
den Hertog, Heleen
Kraayeveld, Petra
Lycklama a Nijeholt, Geert
Flach, Zwenneke
Hill, Michael
Rempel, Jeremy
Lowe, Ann
Lingsma, Hester
Nieboer, Daan
del Zoppo, Gregory
Rijken, Dingeman
Cohen, Adam
Gurewich, Victor
van der Lugt, Aad
Smagge, Lucas
Sterrenberg, Martin
El Ghannouti, Naziha
Priem, Debby
Batenburg, Monique
Ponjee, Eva
Eilander, Rieke
de Meris, Joke
Dofferhoff-Vermeulen, Tamara
den Hartog, Sanne
Kremer, Stijn
Heiligers, Leontien
Lansbergen-Engel, Angela
- License Information
-
More Information
Article History
Received: 11 April 2022
Accepted: 25 July 2022
First Online: 9 August 2022
Declarations
:
: The medical ethical committee of the Erasmus MC University Medical Center in Rotterdam approved this study in 2019 (MEC number: 2019-0001). Written informed consent (deferred) for trial participation and their anonymized information to be published will be obtained from patient(s) or their legal representatives.
: Not applicable.
: DD and AvdL report unrestricted grants from Stryker, Penumbra, Medtronic, Cerenovus, Thrombolytic Science, LLC, Dutch Heart Foundation, Brain Foundation Netherlands, The Netherlands Organization for Health Research and Development, and Health Holland Top Sector Life Sciences & Health for research, paid to institution. WM receives consulting fees from Berry Consultants, LLC which has a contract with and receives funds from Thrombolytic Science, LLC. AW is Chief Executive Officer (CEO) of Thrombolytic Science, LLC. VG is Chief Scientific Officer (CSO) of Thrombolytic Science, LLC. All other authors report no competing interests.
